[Pneumo- and cardiotoxic side effects following combination chemotherapy with epirubicin and ifosfamide].
Franzen
D
D
Medizinische Klinik III, Universität Köln.
Pöhler
E
E
Hilger
H H
HH
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D015412:Mastectomy, Segmental; D012131:Respiratory Insufficiency / Q000139:chemically induced*
D015251:Epirubicin; D007069:Ifosfamide
Pneumo- und kardiotoxische Nebenwirkungen nach Kombinationschemotherapie mit Epirubicin und Ifosfamid.